Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD)
Industry / private company
Location:
Kenilworth, NJ,
United States (USA) (US)
ISNI: 0000000122600793
ROR: https://ror.org/02891sr49
Spatial analyses of immune cell infiltration in cancer: current methods and future directions. A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer (2023)
Page DB, Broeckx G, Jahangir CA, Verbandt S, Gupta RR, Thagaard J, Khiroya R, et al.
Journal article, Review article
Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the international immuno-oncology biomarker working group (2023)
Thagaard J, Broeckx G, Page DB, Jahangir CA, Verbandt S, Kos Z, Gupta R, et al.
Journal article, Review article
Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States (2023)
Huang M, Fasching P, Haiderali A, Xue W, Yang C, Pan W, Zhou ZY, et al.
Journal article
Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1 (2022)
Huang M, O'Shaughnessy J, Haiderali A, Pan W, Hu P, Chaudhuri M, Le Bailly De Tilleghem C, et al.
Journal article
Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (2022)
Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, et al.
Conference contribution
HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022)
Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al.
Conference contribution
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis (2022)
Cortes J, Haiderali A, Huang M, Pan W, Fox GE, Park J, Frederickson AM, et al.
Conference contribution
Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy (2022)
Fasching P, Huang M, Haiderali A, Xue W, Pan W, Karantza V, Yang F, et al.
Conference contribution
Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry (2022)
Mohr P, Scherrer E, Alar V, Assaf C, Beissert S, Berking C, Eigentler T, et al.
Conference contribution
Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer (2022)
Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou ZY, Hu P, et al.
Journal article